PubMed · 1859515
Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.
Abstract
Ticlopidine (Ticlodone: CAS 55142-85-3) is able to develop a positive effect on claudication in patients affected by peripheral atherosclerotic disease (PAD). It is also known that ticlopidine decreases fibrinogen levels in plasma. 15 PAD patients treated with ticlopidine for 3 months were studied, evaluating the drug's effect both on maximum walking distance and on fibrinogen. Plasma fibrinogen as coagulable protein, fibrinogen antigen (Partigen method), 125I-fibrinogen survival, euglobulin lysis time and plasminogen were determined with the aim of clarifying if the decrease of plasma fibrinogen induced by ticlopidine is due to an increased destruction of a decreased production of the molecule. The normal levels of all tests before and after therapy both in ticlopidine treated patients and in the control group (acetylsalicylic acid + dipyridamol) indicate that the two hypotheses are not true. It is proposed that ticlopidine developing the known effect in decreasing the binding of fibrinogen to platelets induces a decrease only of activated fibrinogen.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
M L Randi, M Mares, F Fabris, T Tison, E Barbone, A Girolami. 1991. Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.. https://pubmed.health/record/pubmed%3A1859515/decrease-of-fibrinogen-in-patients-with-peripheral-atherosclerotic-disease-by-ticlopidine
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.